Loading…

BCG vaccine: Worrying proposal for COVID-19

Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be fr...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2021-01, Vol.39 (3), p.460-462
Main Authors: Sarinho, Emanuel, Goudouris, Ekaterini, Solé, Dirceu
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3
cites cdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3
container_end_page 462
container_issue 3
container_start_page 460
container_title Vaccine
container_volume 39
creator Sarinho, Emanuel
Goudouris, Ekaterini
Solé, Dirceu
description Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.
doi_str_mv 10.1016/j.vaccine.2020.12.026
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X20315930</els_id><sourcerecordid>2474462057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</originalsourceid><addsrcrecordid>eNqFkctKAzEUhoMotlYfQRlwI8jUXGcSF4pWrYVCN952Ic1kNGU6qcm00Lc3pbWoG1eBk-98yfkPAMcIdhFE2cWku1Ba29p0McSxhrsQZzugjXhOUswQ3wXtWKEpRfCtBQ5CmEAIGUFiH7QIIRQRyNrg_LbXTzamy-TVeb-09Xsy827mgqqS0vmkN3oZ3KVIHIK9UlXBHG3ODnh-uH_qPabDUX_QuxmmmgrWpCLTHGdaCaOQYlwwRlUBiUaiKLimY6OoopxxQ3GZU6HJOGMMlqpEXBSQa9IBV2vvbD6emkKbuvGqkjNvp8ovpVNW_r6p7Yd8dwuZ55QRmEfB2Ubg3efchEZObdCmqlRt3DxITHPECOc5jejpH3Ti5r6O460oSjMM2UrI1pT2LgRvyu1nEJSrdciJ3IQoV-uQCMsYfuw7-TnJtus7_whcrwET81xY42XQ1tTaFNYb3cjC2X-e-AJBvpwQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474462057</pqid></control><display><type>article</type><title>BCG vaccine: Worrying proposal for COVID-19</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Sarinho, Emanuel ; Goudouris, Ekaterini ; Solé, Dirceu</creator><creatorcontrib>Sarinho, Emanuel ; Goudouris, Ekaterini ; Solé, Dirceu</creatorcontrib><description>Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2020.12.026</identifier><identifier>PMID: 33341305</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adaptive immunity ; Age ; Bacillus Calmette-Guerin vaccine ; BCG ; BCG Vaccine ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Drug dosages ; Epidemiology ; Epigenetics ; Humans ; Hypotheses ; Immunity ; Immunization, Secondary ; Immunodeficiency ; Infections ; Infectious diseases ; Innate ; Mortality ; Pandemics ; Pneumonia ; Public health ; SARS-CoV-2 ; Scientific papers ; Severe acute respiratory syndrome coronavirus 2 ; Tuberculosis ; Tuberculosis - prevention &amp; control ; Vaccines</subject><ispartof>Vaccine, 2021-01, Vol.39 (3), p.460-462</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</citedby><cites>FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</cites><orcidid>0000-0002-1937-9124</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33341305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarinho, Emanuel</creatorcontrib><creatorcontrib>Goudouris, Ekaterini</creatorcontrib><creatorcontrib>Solé, Dirceu</creatorcontrib><title>BCG vaccine: Worrying proposal for COVID-19</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.</description><subject>Adaptive immunity</subject><subject>Age</subject><subject>Bacillus Calmette-Guerin vaccine</subject><subject>BCG</subject><subject>BCG Vaccine</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Drug dosages</subject><subject>Epidemiology</subject><subject>Epigenetics</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Immunity</subject><subject>Immunization, Secondary</subject><subject>Immunodeficiency</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Innate</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Pneumonia</subject><subject>Public health</subject><subject>SARS-CoV-2</subject><subject>Scientific papers</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Tuberculosis</subject><subject>Tuberculosis - prevention &amp; control</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkctKAzEUhoMotlYfQRlwI8jUXGcSF4pWrYVCN952Ic1kNGU6qcm00Lc3pbWoG1eBk-98yfkPAMcIdhFE2cWku1Ba29p0McSxhrsQZzugjXhOUswQ3wXtWKEpRfCtBQ5CmEAIGUFiH7QIIRQRyNrg_LbXTzamy-TVeb-09Xsy827mgqqS0vmkN3oZ3KVIHIK9UlXBHG3ODnh-uH_qPabDUX_QuxmmmgrWpCLTHGdaCaOQYlwwRlUBiUaiKLimY6OoopxxQ3GZU6HJOGMMlqpEXBSQa9IBV2vvbD6emkKbuvGqkjNvp8ovpVNW_r6p7Yd8dwuZ55QRmEfB2Ubg3efchEZObdCmqlRt3DxITHPECOc5jejpH3Ti5r6O460oSjMM2UrI1pT2LgRvyu1nEJSrdciJ3IQoV-uQCMsYfuw7-TnJtus7_whcrwET81xY42XQ1tTaFNYb3cjC2X-e-AJBvpwQ</recordid><startdate>20210115</startdate><enddate>20210115</enddate><creator>Sarinho, Emanuel</creator><creator>Goudouris, Ekaterini</creator><creator>Solé, Dirceu</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1937-9124</orcidid></search><sort><creationdate>20210115</creationdate><title>BCG vaccine: Worrying proposal for COVID-19</title><author>Sarinho, Emanuel ; Goudouris, Ekaterini ; Solé, Dirceu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptive immunity</topic><topic>Age</topic><topic>Bacillus Calmette-Guerin vaccine</topic><topic>BCG</topic><topic>BCG Vaccine</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Drug dosages</topic><topic>Epidemiology</topic><topic>Epigenetics</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Immunity</topic><topic>Immunization, Secondary</topic><topic>Immunodeficiency</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Innate</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Pneumonia</topic><topic>Public health</topic><topic>SARS-CoV-2</topic><topic>Scientific papers</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Tuberculosis</topic><topic>Tuberculosis - prevention &amp; control</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarinho, Emanuel</creatorcontrib><creatorcontrib>Goudouris, Ekaterini</creatorcontrib><creatorcontrib>Solé, Dirceu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarinho, Emanuel</au><au>Goudouris, Ekaterini</au><au>Solé, Dirceu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BCG vaccine: Worrying proposal for COVID-19</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2021-01-15</date><risdate>2021</risdate><volume>39</volume><issue>3</issue><spage>460</spage><epage>462</epage><pages>460-462</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33341305</pmid><doi>10.1016/j.vaccine.2020.12.026</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-1937-9124</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2021-01, Vol.39 (3), p.460-462
issn 0264-410X
1873-2518
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745307
source ScienceDirect Freedom Collection 2022-2024
subjects Adaptive immunity
Age
Bacillus Calmette-Guerin vaccine
BCG
BCG Vaccine
Coronaviruses
COVID-19
COVID-19 vaccines
Drug dosages
Epidemiology
Epigenetics
Humans
Hypotheses
Immunity
Immunization, Secondary
Immunodeficiency
Infections
Infectious diseases
Innate
Mortality
Pandemics
Pneumonia
Public health
SARS-CoV-2
Scientific papers
Severe acute respiratory syndrome coronavirus 2
Tuberculosis
Tuberculosis - prevention & control
Vaccines
title BCG vaccine: Worrying proposal for COVID-19
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A50%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BCG%20vaccine:%20Worrying%20proposal%20for%20COVID-19&rft.jtitle=Vaccine&rft.au=Sarinho,%20Emanuel&rft.date=2021-01-15&rft.volume=39&rft.issue=3&rft.spage=460&rft.epage=462&rft.pages=460-462&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2020.12.026&rft_dat=%3Cproquest_pubme%3E2474462057%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2474462057&rft_id=info:pmid/33341305&rfr_iscdi=true